Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Influenza vaccines: challenges and solutions.

Literature DB >> 25766291

Influenza vaccines: challenges and solutions.

Abstract

Vaccination is the best method for the prevention and control of influenza. Vaccination can reduce illness and lessen severity of infection. This review focuses on how currently licensed influenza vaccines are generated in the U.S., why the biology of influenza poses vaccine challenges, and vaccine approaches on the horizon that address these challenges.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 25766291 PMCID： PMC4362519 DOI： 10.1016/j.chom.2015.02.012

Source DB: PubMed Journal: Cell Host Microbe ISSN： 1931-3128 Impact factor: 21.023

46 in total

1. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Authors: Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli
Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129

Review 2. Live attenuated influenza vaccine.

Authors: Hong Jin; Kanta Subbarao
Journal: Curr Top Microbiol Immunol Date: 2015 Impact factor: 4.291

Review 3. Adjuvanted influenza vaccines.

Authors: Orli Even-Or; Sarit Samira; Ronald Ellis; Eli Kedar; Yechezkel Barenholz
Journal: Expert Rev Vaccines Date: 2013-09 Impact factor: 5.217

Review 4. Development of live attenuated influenza vaccines against pandemic influenza strains.

Authors: Kathleen L Coelingh; Catherine J Luke; Hong Jin; Kawsar R Talaat
Journal: Expert Rev Vaccines Date: 2014-05-28 Impact factor: 5.217

5. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors: Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal: Proc Natl Acad Sci U S A Date: 2012-05-21 Impact factor: 11.205

6. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors: K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal: Lancet Date: 2001-06-16 Impact factor: 79.321

Review 7. Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors: Florian Krammer; Peter Palese
Journal: Curr Opin Virol Date: 2013-08-24 Impact factor: 7.090

8. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

Authors: Richard D Antrobus; Tamara K Berthoud; Caitlin E Mullarkey; Katja Hoschler; Lynda Coughlan; Maria Zambon; Adrian V S Hill; Sarah C Gilbert
Journal: Mol Ther Date: 2013-07-08 Impact factor: 11.454

9. New world bats harbor diverse influenza A viruses.

Authors: Suxiang Tong; Xueyong Zhu; Yan Li; Mang Shi; Jing Zhang; Melissa Bourgeois; Hua Yang; Xianfeng Chen; Sergio Recuenco; Jorge Gomez; Li-Mei Chen; Adam Johnson; Ying Tao; Cyrille Dreyfus; Wenli Yu; Ryan McBride; Paul J Carney; Amy T Gilbert; Jessie Chang; Zhu Guo; Charles T Davis; James C Paulson; James Stevens; Charles E Rupprecht; Edward C Holmes; Ian A Wilson; Ruben O Donis
Journal: PLoS Pathog Date: 2013-10-10 Impact factor: 6.823

Review 10. New vaccines against influenza virus.

Authors: Young-Tae Lee; Ki-Hye Kim; Eun-Ju Ko; Yu-Na Lee; Min-Chul Kim; Young-Man Kwon; Yinghua Tang; Min-Kyoung Cho; Youn-Jeong Lee; Sang-Moo Kang
Journal: Clin Exp Vaccine Res Date: 2013-12-18

121 in total

1. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.

Authors: Yanmei Hu; Rami Musharrafieh; Chunlong Ma; Jiantao Zhang; Donald F Smee; William F DeGrado; Jun Wang
Journal: Antiviral Res Date: 2017-01-10 Impact factor: 5.970

2. Toll-like receptor 3 in nasal CD103⁺ dendritic cells is involved in immunoglobulin A production.

Authors: H Takaki; S Kure; H Oshiumi; Y Sakoda; T Suzuki; A Ainai; H Hasegawa; M Matsumoto; T Seya
Journal: Mucosal Immunol Date: 2017-06-15 Impact factor: 7.313

Review 3. The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.

Authors: David Skurnik; Colette Cywes-Bentley; Gerald B Pier
Journal: Expert Rev Vaccines Date: 2016-03-16 Impact factor: 5.217

4. Heterologous viral protein interactions within licensed seasonal influenza virus vaccines.

Authors: Marina Koroleva; Frances Batarse; Savannah Moritzky; Carole Henry; Francisco Chaves; Patrick Wilson; Florian Krammer; Katherine Richards; Andrea J Sant
Journal: NPJ Vaccines Date: 2020-01-10 Impact factor: 7.344

5. Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors: Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal: J Virol Date: 2021-03-03 Impact factor: 5.103

Review 6. From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses.

Authors: Julijan Kabiljo; Johannes Laengle; Michael Bergmann
Journal: Cell Death Discov Date: 2020-06-11

10. Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses.

Authors: Yanmei Hu; Yuanxiang Wang; Fang Li; Chunlong Ma; Jun Wang
Journal: Eur J Med Chem Date: 2017-04-20 Impact factor: 6.514